Combination therapy in hypertension: An update

Diabetology and Metabolic Syndrome

Volumn 2, Issue 1, 2010, Pages

  Kalra, Sanjay ^a   Kalra, Bharti ^a   Agrawal, Navneet ^b  

^a Bharti Hospital and Bharti Research Institute of Diabetes and Endocrinology   (India)

^b G R MEDICAL COLLEGE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; AMLODIPINE PLUS OLMESARTAN; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL PLUS CHLORTALIDONE; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CAPTOPRIL PLUS HYDROCHLOROTHIAZIDE; CHLORTALIDONE; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL PLUS HYDROCHLOROTHIAZIDE; FELODIPINE; HYDROCHLOROTHIAZIDE; IRBESARTAN; LISINOPRIL; LOSARTAN; METOPROLOL; MOEXIPRIL; OLMESARTAN; PROPRANOLOL; RAMIPRIL; TELMISARTAN; TRANDOLAPRIL PLUS VERAPAMIL; TRIAMTERENE; TRICHLORMETHIAZIDE; UNINDEXED DRUG; VALSARTAN;

BLOOD PRESSURE REGULATION; CHRONIC KIDNEY FAILURE; COMORBIDITY; DIABETES MELLITUS; DRUG MECHANISM; DYSLIPIDEMIA; HEART FAILURE; HUMAN; HYPERTENSION; METABOLIC SYNDROME X; PERIPHERAL EDEMA; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIDE EFFECT; THYROID DISEASE;

EID: 77954484572     PISSN: None     EISSN: 17585996     Source Type: Journal    
DOI: 10.1186/1758-5996-2-44     Document Type: Review

References (79)

1. Standards of medical care in diabetes. American Diabetes Association, Diabetes Care 2010 33 Suppl 1 11 61
2. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. KL Ong BM Cheung YB Man CP Lau KS Lam, Hypertension 2007 49 69 75 10.1161/01.HYP.0000252676.46043.18 17159087
3. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. S Lewington R Clarke N Qizilbash R Peto R Collins for the Prospective Studies Collaboration, Lancet 2002 360 1903 1913 10.1016/S0140-6736(02)11911-8 12493255
4. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. L Hansson A Zanchetti SG Carruthers B Dahlöf D Elmfeldt S Julius J Ménard KH Rahn H Wedel S Westerling, Lancet 1998 351 1755 1762 10.1016/S0140-6736(98)04311-6 9635947 (Pubitemid 28269185)
5. Implications of small reductions in diastolic blood pressure for primary prevention. NR Cook J Cohen PR Hebert JO Taylor CH Hennekens, Arch Intern Med 1995 155 701 709 10.1001/archinte.155.7.701 7695458
6. Emerging Insights in the First-Step Use of Antihypertensive Combination Therapy. K Norris JM Neutel, J Clin Hypertens (Greenwich) 2007 9 12 Suppl 5 5 14 10.1111/j.1524-6175.2007.07807.x 18046107
7. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003 42 1206 1252 10.1161/01.HYP.0000107251.49515.c2 14656957
8. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003 21 1011 1053 10.1097/00004872-200306000-00001 12777938
9. Hypertension management: results of a new national survey for the hypertension education foundation: Harris interactive. M Moser SS Franklin, J Clin Hypertens (Greenwich) 2007 9 316 323 10.1111/j.1524-6175.2007.07152.x 17485966
10. Losartan potassium as initial therapy in patients with severe hypertension. MC Dunlay V Fitzpatrick S Chrysant EA Francischetti AI Goldberg CS Sweet, J Hum Hypertens 1995 9 861 867 8583463
11. Candesartan cilexetil enhances blood pressure reduction severe (state 3, JNC-VI) hypertensive patients inadequately controlled with HCTZ. S Oparil E Ripley on behalf of Candesartan Study Investigators, Am J Hypertens 1998 11 4 part 1 121A 10.1016/S0895-7061(97)91163-8
12. Effects and tolerability of irbesartan versus enalapril in patients with severe hypertension. P Larochelle JM Flack TC Marbury P Sareli EM Krieger RA Reeves for the Irbesartan Multicenter Investigators, Am J Cardiol 1997 80 1613 1615 10.1016/S0002-9149(97)00784-4 9416950
13. Valsartan and atenolol in patients with severe essential hypertension. R Cifkova J Peleska J Hradec E Pintérov K Zeman P Oddou-Stock J Thirlwell F Botteri, J Hum Hypertens 1998 12 563 567 10.1038/sj.jhh.1000615 9759992
14. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. L Hansson A Zanchetti SG Carruthers B Dahlöf D Elmfeldt S Julius J Ménard KH Rahn H Wedel S Westerling for the HOT Study Group, Lancet 1998 351 1755 1762 10.1016/S0140-6736(98)04311-6 9635947 (Pubitemid 28269185)
15. Results of Treatment With Telmisartan-Amlodipine in Hypertensive Patients. TW Littlejohn CR Majul R Olvera M Seeber M Kobe R Guthrie W Oigman, The journal of clinical hypertension 2009 11 207 213 10.1111/j.1751-7176.2009. 00098.x 19614805
16. Olmesartan medoxomil/amlodipine. M Sanford SJ Keam, Drugs 2009 69 717 729 10.2165/00003495-200969060-00005 19405551
17. Comparison of a felodipine-metoprolol combination tablet vs each component alone as antihypertensive therapy. The German Multicentre Study Group. J Hoffmann, Blood Press Suppl 1993 1 30 36 8173688
18. Long-term evaluation of combined antihypertensive therapy with lisinopril and a thiazide diuretic in patients with essential hypertension. T Ishimitsu S Yagi A Ebihara Y Doi A Domae A Shibata M Kimura Y Sugishita E Sagara T Sakamaki K Murata, Jpn Heart J 1997 38 831 840 9486936
19. -2007 ESH-ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). G Mansia G De Backer A Dominiczak R Cifkova R Fagard G Germano G Grassi AM Heagerty SE Kjeldsen S Laurent K Narkiewicz L Ruilope A Rynkiewicz RE Schmieder HA Struijker Boudier A Zanchetti, Blood Press 2007 16 135 232 10.1080/08037050701461084 17846925
20. Combination Therapy With Renin-Angiotensin-Aldosterone Receptor Blockers for Hypertension: How Far Have We Come? MR Weir GL Bakris, J Clin Hypertens (Greenwich) 2008 10 146 152 10.1111/j.1751-7176.2008.07439.x 18256579
21. Does diuretic therapy increase the risk of renal cell carcinoma? E Grossman FH Messerli U Goldbourt, Am J Cardiol 1999 83 1090 1093 10.1016/S0002-9149(99)00021-1 10190526
22. Beta-Blockers and Diuretics: To Use or Not to Use. FH Messerli E Grossman, Am J Hypertens 1999 12 Pt 1-2 157S 163S 10.1016/S0895-7061(99)00220-4 10619596
23. Beta-adrenergic antagonists in hypertension: a review of the evidence. TS Warmack MA Estes S Heldenbrand AM Franks, Ann Pharmacother 2009 43 2031 2043 10.1345/aph.1M381 19934392
24. Baseline heart rate, antihypertensive treatment, and prevention of cardiovascular outcomes in ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial). NR Poulter JE Dobson PS Sever B Dahlöf H Wedel NR Campbell, J Am Coll Cardiol 2009 54 1154 1161 10.1016/j.jacc.2009.04.087 19761936
25. Diuretics, b-blockers, and the risk for sudden cardiac death in hypertensive patients. AW Hoes DE Grobbee J Lubsen AJ Man in'tVeld E van der Does A Hofman, Ann Intern Med 1995 123 482 487
26. The effect of perindopril and hydrochlorothiazide alone and in combination on blood pressure and on the renin-angiotensin system in hypertensive subjects. CL Brown CI Backhouse JC Grippat JP Santoni, Eur J Clin Pharmacol 1990 39 327 332 10.1007/BF00315404 2076713
27. Antihypertensive effectiveness of low-dose lisinopril-hydrochlorothiazide combination: a large multicenter study. Lisinopril-Hydrochlorothiazide Group. SG Chrysant, Arch Intern Med 1994 154 737 743 10.1001/archinte.154.7.737 8147677
28. Efficacy and safety of fixed combination of perindopril and indapamide in type 2 diabetes: results from ADVANCE in context of available evidence. J Hypertens 2008 26 Suppl 3 23S 30S 10.1097/01.hjh.0000334603.78628.33
29. The effects of irbesartan added to hydrochlorothiazide for the treatment of hypertension in patients non-responsive to hydrochlorothiazide alone. J Rosenstock l Rossi CS Lin D MacNeil M Osbakken, J Clin Pharm Ther 1998 23 433 440 10.1046/j.1365-2710.1998.00184.x 10048504
30. Efficacy and safety of irbesartan/HcTZ combination therapy as initial treatment for rapid control of severe hypertension. JM Neutel SS Franklin S Oparil A Bhaumik A Ptaszynska P Lapuerta, J Clin Hypertens (Greenwich) 2006 8 850 857 10.1111/j.1524-6175.2006.05676.x 17170610
31. Long-term safety and antihypertensive efficacy of irbesartan: pooled results of five open-label studies. T Littlejohn iii R Saini K Kassler-Taub SG Chrysant T Marbury, Clin Exp Hypertens 1999 21 8 1273 1295 10.3109/ 10641969909070849 10574413
32. Dose-related efficacy of irbesartan for hypertension: an integrated analysis. RA Reeves CS Lin K Kassler-Taub H Pouleur, Hypertension 1998 31 1311 1316 9622147
33. Efficacy of low-dose hydrochlorothiazide in combination with telmisartan on early morning blood pressure in uncontrolled hypertensive patients. S Makita A Abiko Y Naganuma M Tamada M Nakamura, Clin Exp Hypertens 2009 31 105 115 10.1080/10641960802621259 19330600
34. ONgoing Evaluation of depressor effect And Safety of combination therapy with Telmisartan and low-dose hydrochlorothiazide (ONEAST)Study Group. Effect of switching from amlodipine to combination therapy with telmisartan and low-dose hydrochlorothiazide. K Ando M Isshiki K Takahashi, Hypertens Res 2009 32 748 752 10.1038/hr.2009.101 19590506
35. Combination therapy with Renin-Angiotensin-aldosterone receptor blockers for hypertension: how far have we come? MR Weir GL Bakris, J Clin Hypertens (Greenwich) 2008 10 146 152 10.1111/j.1751-7176.2008.07439.x 18256579
36. Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes. M Pahor BM Psaty MH Alderman WB Applegate JD Williamson CD Furberg, Diabetes Care 2000 23 888 892 10.2337/diacare.23.7.888 10895836
37. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET)in patients with hypertension and NIDDM. P Tatti M Pahor RP Byington PD Mauro R Guarisco G Strollo F Strollo, Diabetes Care 1998 21 597 603 10.2337/diacare.21.4.597 9571349
38. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. SE Nissen EM Tuzcu P Libby PD Thompson M Ghali D Garza L Berman H Shi E Buebendorf EJ Topol, JAMA 2004 292 2217 2225 10.1001/jama.292.18. 2217 15536108
39. Amlodipine Added to Quinapril vs Quinapril Alone for the Treatment of Hypertension in Diabetes: The Amlodipine in Diabetes (ANDI)Trial. S Tobe K Kawecka-Jaszcz F Zannad G Vetrovec R Patni H Shi, J Clin Hypertens 2007 9 120 127 10.1111/j.1524-6175.2007.06949.x
40. Targeting mechanisms of hypertensive vascular disease with dual calcium channel and renin-angiotensin system blockade. MR Weir, J Hum Hypertens 2007 21 770 779 10.1038/sj.jhh.1002254 17597800
41. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE) a randomised trial against atenolol. B Dahlof RB Devereux SE Kjeldsen S Julius G Beevers U De Faire F Fyhrquist H Ibsen K Kristiansson O Lederballe-Pedersen LH Lindholm MS Nieminen P Omvik S Oparil H Wedel for LIFE Study Group, Lancet 2002 359 995 1003 10.1016/S0140-6736(02)08089-3 11937178 (Pubitemid 34286536)
42. Effect of telmisartan amlodipine combination at different doses on urinary albumin excretion in hypertensive diabetic patients with microalbuminuria. R Fogari G Derosa A Zoppi P Preti P Lazzari M Destro E Fogari A Rinaldi A Mugellini, Am J Hypertens 2007 20 417 422 10.1016/j.amjhyper.2006. 10.002 17386350
43. Combined blockade of the reninangiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists. M Azizi J Menard, Circulation 2004 109 2492 2499 10.1161/01.CIR.0000131449.94713.AD 15173039
44. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes, the candesartan and lisinopril microalbuminuria (CALM)study. CE Mogensen S Neldam I Tikkanen S Oren R Viskoper RW Watts ME Cooper, BMJ 2000 321 1440 1444 10.1136/bmj.321.7274.1440 11110735
45. Effects of combination treatment with losartan and trandolapril on office and ambulatory blood pressures in non-diabetic renal disease, a CoopEraTE-abp substudy. NN Nakao H Seno H Kasuga T Toriyama H Kawahara M Fukagawa, Am J Nephrol 2004 24 543 548 10.1159/000081953 15528874
46. Combination treatment of angiotensin-ii receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE) a randomised controlled trial. N Nakao A Yoshimura H Morita M Takada T Kayano T Ideura, Lancet 2003 361 117 124 10.1016/S0140-6736(03)12229-5 12531578 (Pubitemid 36092015)
47. Comparative impact of enalapril, candesartan or metoprolol alone or in combination on ventricular remodelling in patients with congestive heart failure. RS McKelvie JL Rouleau M White R Afzal JB Young AP Maggioni P Held S Yusuf, Eur Heart J 2003 24 1727 1734 10.1016/S0195-668X(03)00477-9 14522567
48. ACE inhibitor or angiotensin receptor blockade, impact on potassium in renal failure. GL Bakris M Siomos D Richardson I Janssen WK Bolton L Hebert R Agarwal D Catanzaro, Kidney Int 2000 58 2084 2092 10.1111/j.1523-1755.2000. 00381.x 11044229
49. High dose of enalapril impairs the response to erythropoietin treatment in hemodialysis patients. S Albitar R Genin M Fen-Chong MO Serveaux B Bourgeon, Nephrol Dial Transplant 1998 13 1206 1210 10.1093/ndt/13.5.1206 9623555
50. Comparison of different fixed antihypertensive combination drugs a double-blind, placebo controlled parallel group study. PW De Leeuw T Notter P Zilles, J Hypertens 1997 15 87 91 10.1097/00004872-199715010-00009 9050975
51. Evaluation of the effects of fixed combinations of sustained-release verapamil/trandolapril versus captopril/hydrochlorothiazide on metabolic and electrolyte parameters in patients with essential hypertension. AAR Cifkov R Nakov AE NovozAmsk Z Hejl Z Petrzílkova R Poledne P Stvek D Compagnone, J Hum Hypertens 2000 14 347 354 10.1038/sj.jhh.1001014 10878692
52. Comparison of benazepril-amlodipine and captopril-thiazide combinations in the management of mild-to-moderate hypertension. E Malacco S Piazza R Carretta S Di Somma A Mugellini F Bertocchi P Palatini, Int J Clin Pharmacol Ther 2002 40 263 269 12078940
53. Efficacy and safety of delapril plus manidipine compared with enalapril plus hydrochlorthiazide in mild to moderate essential hypertension: results of a randomized trial. A Mugellini J Dobovisek D Planinc G Cremonesi R Fogari, Clin Ther 2004 26 1419 1426 10.1016/j.clinthera.2004.09.018 15531004
54. The effects of antihypertensive combination therapy on lipid and glucose metabolism: hydrochlorothiazide plus sotalol vs. hydrochlorothiazide plus captopril. M Middeke WO Richter P Schwandt H Holzgreve, Int J Clin Pharmacol Ther 1997 35 231 234 9208337
55. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOTBPLA). NR Poulter H Wedel B Dahlof PS Sever DG Beevers M Caulfield SE Kjeldsen A Kristinsson GT McInnes J Mehlsen M Nieminen E O'Brien J Ostergren S Pocock, Lancet 2005 366 907 913 10.1016/S0140-6736(05)67186-3 16154017
56. Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. G Bakris M Molitch A Hewkin M Kipnes P Sarafidis K Fakouhi P Bacher J Sowers STAR Investigators, Diabetes Care 2006 29 2592 2597 10.2337/dc06-1373 17130190
57. Antihypertensive therapy with verapamil SR plus trandolapril versus atenolol plus chlorthalidone on glycemic control. H Holzgreve R Nakov K Beck HU Janka, Am J Hypertens 2003 16 381 386 10.1016/S0895-7061(03)00062-1 12745200
58. Blood pressure and aortic elastic properties: verapamil SR/trandolapril compared to a metoprolol/hydrochlorothiazide combination therapy. GR Breithaupt K Ogler G Gerhardt G Lehmann T Notter GG Belz, Int J Clin Pharmacol Ther 1998 36 425 431 9726695
59. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. K Jamerson MA Weber GL Bakris B Dahlof B Pitt V Shi A Hester J Gupte M Gatlin EJ Velazquez ACCOMPLISH Trial Investigators, N Engl J Med 2008 359 2417 2428 10.1056/NEJMoa0806182 19052124
60. Comparison of the antihypertensive effects of the fixed dose combination enalapril 10 mg/nitrendipine 20 mg vs losartan 50 mg/hydrochlorothiazide 12.5 mg, assessed by 24-h ambulatory blood pressure monitoring, in essential hypertensive patients. A De la Sierra B Gil-Extremera C Calvo C Campo J García-Puig E Mrquez J Olivn CA Roca S Sanz de Castro C Pontes J Delgadillo, J Hum Hypertens 2004 18 215 22 10.1038/sj.jhh.1001655 14973517
61. Risk factors for stroke in type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS). TM Davis H Millns IM Stratton RR Holman RC Turner, Arch Intern Med 1999 159 1097 1103 10.1001/archinte.159.10.1097 10335687
62. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. EJ Lewis LG Hunsicker WR Clarke T Berl MA Pohl JB Lewis E Ritz RC Atkins R Rohde I Raz for the Collaborative Study Group, N Engl J Med 2001 345 851 860 10.1056/NEJMoa011303 11565517
63. Fixed combination of amlodipine and atorvastatin in cardiovascular risk management: patient perspectives. M Devabhaktuni S Bangalore, Vasc Health Risk Manag 2009 5 377 387 19475775
64. Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes. Y Miura N Yamamoto S Tsunekawa S Taguchi Y Eguchi N Ozaki Y Oiso, Diabetes Care 2005 28 737 738 10.2337/diacare.28.3.757 (Pubitemid 40315351)
65. Effect of Telmisartan on Cholesterol Levels in Patients with Hypertension - Saga Telmisartan Aggressive Research (STAR). T Inoue T Morooka K Moroe H Ikeda K Node, Horm Metab Res 2007 39 372 376 10.1055/s-2007-976544 17533580
66. Molecular characterization of new selective peroxisome proliferators-activated receptor modulators with angiotensine receptor blocking activity. M Schupp M Clemenz R Gineste H Witt J Janke S Helleboid N Hennuyer P Ruiz T Unger B Staels U Kintscher, Diabetes 2005 54 3442 3452 10.2337/diabetes.54.12.3442 16306360
67. Overview of randomized trials of angiotensin-converting enzyme inhibitors on the mortality and morbidity in patients with heart failure. R Garg S Yusuf, JAMA 1995 18 1450 1455 10.1001/jama.273.18.1450
68. Beta-blockers in heart failure. The 'new wave' of clinical trials. H Krum, Drugs 1999 58 203 210 10.2165/00003495-199958020-00001 10473016
69. Carvedilol Prospective Randomized Cumulative Survival Study Group. Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure: the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. JL Rouleau EB Roecker M Tendera P Mohacsi H Krum HA Katus MB Fowler AJ Coats A Castaigne A Scherhag TL Holcslaw M Packer, J Am Coll Cardiol 2004 43 1423 1429 10.1016/j.jacc.2003.11. 037 15093878
70. CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. JJ McMurray J Ostergren K Swedberg CB Granger P Held EL Michelson B Olofsson S Yusuf MA Pfeffer, Lancet 2003 362 767 771 10.1016/S0140-6736(03)14283-3 13678869 (Pubitemid 37093916)
71. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial. JF Mann RE Schmieder M McQueen L Dyal H Schumacher J Pogue X Wang A Maggioni A Budaj S Chaithiraphan K Dickstein M Keltai K Metsärinne A Oto A Parkhomenko LS Piegas TL Svendsen KK Teo S Yusuf, Lancet 2008 372 547 553 10.1016/S0140-6736(08)61236-2 18707986
72. Management of hypertension in chronic kidney disease. P Zamboli L De Nicola R Minutolo V Bertino F Catapano G Conte, Curr Hypertens Rep 2006 8 497 501 10.1007/s11906-006-0029-4 17139806
73. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. KL Ong BM Cheung YB Man KS Lam CP Lau, Hypertension 2007 49 69 75 10.1161/01.HYP.0000252676.46043.18 17159087
74. Drug Treatment of Hypertension in the Elderly: A Meta-Analysis. JT Insua HS Sacks TS Lau J Lau D Reitman D Pagano TC Chalmers, Ann Intern Med 1994 121 355 362 7726892
75. Systolic hypertension in older persons. SI Chaudhry HM Krumholz JM Foody, JAMA 2004 292 1074 1080 10.1001/jama.292.9.1074 15339901
76. Hypertension in the very elderly: Brief review of management. MA Zeglin J Pacos JD Bisognano, Cardiol J 2009 16 379 385 19653187
77. Hypertension in pregnancy and women of childbearing age. SR Yoder LL Thornburg JD Bisognano, Am J Med 2009 122 890 895 10.1016/j.amjmed.2009.03.036 19786154
78. Benefits, challenges, and registerability of the polypill. P Sleight H Pouleur F Zannad, Eur Heart J 2006 27 1651 1656 10.1093/eurheartj/ehi841 16603580
79. Should we be more aggressive in the therapy against cardiovascular risk factors? Should we prescribe statin and aspirin for every diabetic patient, or is it time for a polypill? AO Stirban D Tschoepe, Diabetes Care 2008 31 Suppl 2 226 228 10.2337/dc08-s254